NCT06501924

Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 516 (estimated)
• Sponsor: Applied Biology, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).

Detailed description

DA-005 is a botanical supplement with demonstrated HIF-1a inhibitory action. The ingredients were tested in-vitro and have demonstrated the HIF-1a inhibitory effect. The primary aim of the study is to compare DA-005 to topical minoxidil in the treatment of hair loss (also known as androgenetic alopecia). DA-002 is a topical alpha 1 agonist. The ingredients were tested in-vitro and have demonstrated hair growth effects. The secondary aim of the study is to compare DA-002 to topical minoxidil in the treatment of hair loss (also known as androgenetic alopecia).

Conditions

• Androgenetic Alopecia
• Female Pattern Baldness
• Male Pattern Baldness

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	DA-005	Oral Botanical Supplement HIF-1a inhibitor
DRUG	Topical minoxidil 5%	Topical minoxidil 5%
DRUG	DA-002	Topical Alpha 1 Agonist (GRAS)
DIETARY_SUPPLEMENT	Placebo Oral Tablet	Placebo Oral Tablet
OTHER	Placebo Topical Solution	Placebo Topical Solution

Timeline

• Start date: 2025-01-15
• Primary completion: 2025-10-17
• Completion: 2025-12-12
• First posted: 2024-07-15
• Last updated: 2024-12-19